



NDA 21-172/S-001

Novo Nordisk Pharmaceuticals, Inc.
Attention: Barry Reit, Ph.D.
Vice President, Regulatory Affairs
100 College Road West
Princeton, NJ 08540

Dear Dr. Reit:

Please refer to your supplemental new drug application dated November 12, 2001, received November 13, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for NovoLog Mix 70/30 (70% insulin aspart [rDNA origin] protamine suspension and 30% insulin aspart [rDNA origin] injection).

We acknowledge receipt of your submissions dated March 15 and 22, 2002. Your submission of March 15, 2002, constituted a complete response to our March 4, 2002, action letter.

This supplemental new drug application provides for an additional presentation of a disposable 3 mL NovoLog Mix 70/30 FlexPen Prefilled syringe.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert for NovoLog Mix 70/30 FlexPen Prefilled syringe).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-172/S-001." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Julie Rhee, Regulatory Project Manager, at (301) 827-6424.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures: 1. Marked-up insert
2. Marked-up patient insert for NovoLog Mix 70/30 FlexPen Prefilled syringe

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

David Orloff

5/3/02 12:36:00 PM